Overview

Study of XL418 in Adults With Solid Tumors

Status:
Suspended
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of XL418 in subjects with solid tumors. XL418 is a new chemical entity that inhibits a spectrum of targets, including Akt and p70S6K, that mediate PI3 Kinase / PTEN signaling.
Phase:
Phase 1
Details
Lead Sponsor:
Exelixis